Tumor-associated antigen on colorectal carcinoma cells

The term “tumor-associated antigen on colorectal carcinoma cells” refers broadly to any protein, glycoprotein, carbohydrate structure, or other molecular entity that is abnormally expressed by malignant cells of the colon and rectum compared to normal tissue. These molecules can serve as targets for diagnostic assays and therapeutic interventions—most notably immunotherapies such as monoclonal antibodies and cancer vaccines. However, “tumor-associated antigen” does not refer to one unique molecule but rather encompasses many possible targets including carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), MUC1 mucin protein, among others. Because this designation lacks specificity—it does not identify which particular molecular entity is meant—it cannot be mapped directly onto standard nomenclature used for drug discovery databases. For structured data extraction and downstream applications such as drug-target mapping or biomarker selection in clinical trials of colorectal cancer therapies[1][2][3], it will be necessary to specify exactly which tumor-associated antigen(s) are under consideration. In summary: “Tumor-associated antigen on colorectal carcinoma cells” describes an important concept in oncology but does not correspond to one canonical target suitable for structured annotation without further specification.

Other names

Tumor-associated antigen in colorectal cancerColorectal carcinoma tumor antigenCRC tumor-associated antigen